GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AREV Life Sciences Global Corp (OTCPK:AREVF) » Definitions » Debt-to-Equity

AREV Life Sciences Global (AREV Life Sciences Global) Debt-to-Equity : -0.12 (As of Sep. 2023)


View and export this data going back to 2019. Start your Free Trial

What is AREV Life Sciences Global Debt-to-Equity?

AREV Life Sciences Global's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.11 Mil. AREV Life Sciences Global's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil. AREV Life Sciences Global's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $-0.86 Mil. AREV Life Sciences Global's debt to equity for the quarter that ended in Sep. 2023 was -0.12.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for AREV Life Sciences Global's Debt-to-Equity or its related term are showing as below:

AREVF' s Debt-to-Equity Range Over the Past 10 Years
Min: -6.59   Med: -0.23   Max: 152
Current: -0.13

During the past 13 years, the highest Debt-to-Equity Ratio of AREV Life Sciences Global was 152.00. The lowest was -6.59. And the median was -0.23.

AREVF's Debt-to-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.3 vs AREVF: -0.13

AREV Life Sciences Global Debt-to-Equity Historical Data

The historical data trend for AREV Life Sciences Global's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AREV Life Sciences Global Debt-to-Equity Chart

AREV Life Sciences Global Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.65 -1.09 -1.15 -0.81 -0.03

AREV Life Sciences Global Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.06 -0.03 -0.06 -0.13 -0.12

Competitive Comparison of AREV Life Sciences Global's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, AREV Life Sciences Global's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AREV Life Sciences Global's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AREV Life Sciences Global's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where AREV Life Sciences Global's Debt-to-Equity falls into.



AREV Life Sciences Global Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

AREV Life Sciences Global's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

AREV Life Sciences Global's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AREV Life Sciences Global  (OTCPK:AREVF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


AREV Life Sciences Global Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of AREV Life Sciences Global's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


AREV Life Sciences Global (AREV Life Sciences Global) Business Description

Traded in Other Exchanges
N/A
Address
91 Golden Drive, Unit 18, Coquitlam, BC, CAN, V3K 6R2
AREV Life Sciences Global Corp is a fully integrated, early stage life science discovery enterprise dedicated to delivering solutions to public healthcare metrics through innovations and successful collaborations in the life science industry. The Company's focuses on dedication to generate revenue by way of novel therapeutic approaches to human nutrition and malnutrition, pandemic diseases, and neglected chronic co-morbidities.

AREV Life Sciences Global (AREV Life Sciences Global) Headlines